Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
about
Assessment of platelet inhibition by point-of-care testing in neuroendovascular proceduresNew horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction RegistryBF066, a novel dual target antiplatelet agent without significant bleedingAntiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim DatabaseThe safety of clopidogrel.Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative?Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary interventionEfficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) IIStudy design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemThe scientific achievements of the decades in Korean Acute Myocardial Infarction RegistryInteraction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy AcEffects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study.Clinical presentations, antiplatelet strategies and prognosis of patients with stent thrombosis: an observational study of 140 patients.A bumpy and winding but right path to domestic drug-eluting coronary stents.Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in KoreaClopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Decision-making: stenting in acute myocardial infarction.Clopidogrel in acute coronary syndrome: implications of recent study findings.Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.Vascular disease: obesity and excess weight as modulators of risk.Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Use of cilostazol in percutaneous coronary interventions.Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.Clinical efficacy and safety of cilostazol: a critical review of the literature.Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.A case of stent thrombosis occurred at 5 years after sirolimus-eluting stent implantation.Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction.Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients.Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting.The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease.Primary percutaneous coronary intervention for acute myocardial infarction in the elderly aged ≥75 years.'Smoker's paradox' in young patients with acute myocardial infarction.Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.Benefit of Vasodilating β-Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study.
P2860
Q26823633-9AF0D59B-B8C3-434C-BBDB-C486E099C128Q27015211-3F3329B9-862B-473B-A93E-98437D1ABD72Q27334889-E5605F7E-FFB1-46C7-832B-12ED662659CEQ28550517-1F0D46DA-224E-4C9C-A83E-6B7901869A24Q33392895-34047A5C-EFAE-4749-86D0-4C97F78EEC87Q33396814-613B3FEC-CCFE-4272-8120-C4A359224845Q33426570-6F5EA6DF-EB59-48A4-9BA9-2C15DF4732BAQ33907206-DEB89DB3-769C-472F-A64A-11D07CA3B377Q34114530-A248184D-DC8A-4F57-9CE5-40B5B9DFB7DEQ34451346-9601088B-8968-4F38-B606-B874746B822CQ36036395-59145942-007C-4EAD-8F0B-9F6DE350C637Q36178172-1F9082A1-68CE-485C-B6BD-722EA2BC786DQ36360516-059C8A7B-BB2F-4F25-B2BC-A5AD0AF1311EQ37316783-D3EE3B83-ACBA-46A6-8F07-DF4EAF8FDA44Q37408798-342C5ABD-177A-4475-A25E-77EACF0E8860Q37627874-1640491A-62B2-40C2-9B09-925763E28B3BQ37749818-C8C0D274-6680-4D88-8C2F-2D1D097496E0Q37786639-033877AE-1363-4923-B8DD-E1198991A09FQ37809122-D91C86DD-FB3A-416B-88D5-CD0756B0E121Q37868586-426256EF-CC01-40D2-B865-947EAF1DAC70Q37880741-B6DAB48F-C215-498A-837D-F0E6DBC186E4Q37924998-B77581DC-6EEF-4CD4-AE7D-13CED5323D66Q38012079-46F9775A-720D-44EF-96A6-3BA3A22D3B50Q38016384-1189EFB8-D50D-4201-A1ED-708E847E04F4Q38029492-9BAFA483-3EC7-4BB8-BA7B-7C1F658617B3Q38122999-AC435A57-8D7C-42EE-9913-D883644D5AB7Q38372990-CFC4438B-5D2D-48E2-BA37-431CF183E308Q38403424-20C85FB4-9196-403A-94F8-15F9DC7ECC2FQ39051561-6003DC69-747C-4881-BC48-76D0655F341EQ39066560-97643800-B816-4E5E-9D4F-DBF3A9DCD660Q39794388-8B81178F-94F3-44BC-BECE-4E3AC32E001CQ40774012-D905CCEC-6AAD-4E68-B356-ED9AC1CDCBA9Q41352369-8A504A61-E447-408A-A6F9-5629F3EA893FQ41551745-16548995-D57A-44D9-A3CE-60CB2D59E3DDQ41826841-52A6D28E-DECC-4C4F-8BAF-226627B718B9Q42372849-8E90EE2F-AAB6-42F3-B59B-2641D580EFE8Q43841525-5A736779-374E-4E36-9D2D-39985D183298Q45189184-09A84057-A767-42B7-B274-8DCCED3A5C80Q45888145-8F7DCD61-A225-45F2-A94C-5BF566E5F9D5Q47098635-B5FD01B6-33F8-4D87-9A3C-B18BA351736A
P2860
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Triple versus dual antiplatele ...... taneous coronary intervention.
@en
Triple versus dual antiplatele ...... taneous coronary intervention.
@nl
type
label
Triple versus dual antiplatele ...... taneous coronary intervention.
@en
Triple versus dual antiplatele ...... taneous coronary intervention.
@nl
prefLabel
Triple versus dual antiplatele ...... taneous coronary intervention.
@en
Triple versus dual antiplatele ...... taneous coronary intervention.
@nl
P2093
P1433
P1476
Triple versus dual antiplatele ...... taneous coronary intervention.
@en
P2093
Chang Gyu Park
Chong Jin Kim
Dong Hoon Choi
Dong Joo Oh
Eung Ju Kim
Hong Seog Seo
In Ho Chae
In Whan Seong
Jang Ho Bae
Jei Keon Chae
P304
P356
10.1161/CIRCULATIONAHA.108.822791
P407
P577
2009-06-15T00:00:00Z